PET tracer for visualizing GABAA gamma1 receptor
By developing selective GABAAγ1 receptor forward allosteric regulators and performing radiolabeling, the problem of inability to target and visualize GABAAγ1 receptor in vivo in the prior art is solved, and efficient visualization and diagnostic tools for the receptor are achieved. supply.
Patent Information
- Application Number
- CN202380036566.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-05-03
- Filing Date
- 2023-05-02
- Publication Date
- 2024-12-06
AI Technical Summary
Existing PET tracers are unable to effectively target and visualize the GABAAγ1 receptor in vivo, and lack selective compounds against this receptor.
A selective GABAAγ1 receptor forward allosteric regulator (PAM) was developed to visualize GABAAγ1 receptors with high binding affinity and selectivity by radiolabeling specific compounds for PET or autoradiography techniques.
The efficient visualization of GABAAγ1 receptors is achieved in vivo and in vitro, providing effective tools for diagnosis and research, filling the gap in visualization of GABAAγ1 receptors in the prior art.
Smart Images

Figure BDA0005102513000000021 
Figure BDA0005102513000000041 
Figure BDA0005102513000000052
Abstract
Description
Technical Field
[0001] The present invention relates to radiolabeled GABA useful for medical imaging such as positron emission tomography (PET) and / or autoradiography A γ1 positive allosteric modulator (PAM). Background Art
[0002] The receptors for the major inhibitory neurotransmitter γ-aminobutyric acid (GABA) can be divided into two major categories: (1) GABA A receptor, which is a member of the ligand-gated ion channel superfamily; and (2) GABA B GABA receptor is a member of the G protein-linked receptor family. A The receptor complex is a membrane-bound heteropentameric protein polymer composed primarily of α, β, and γ subunits. A The receptor is a ligand-gated chloride ion channel and is the major mediator of inhibitory neurotransmission in the human brain.
[0003] There are 19 genes encoding GABA A Receptor subunits, which assemble into pentamers with the most common stoichiometry being two α subunits, two β subunits, and one γ subunit. GABA A Subunit combinations give rise to functional, circuit, and behavioral specificity, and their expression is unevenly distributed in the brain. Compared with receptors containing the γ2 subunit, receptors containing GABA A The abundance of γ1 subunit receptors is low (about 100% of GABA A 5%-10% of the total expression of the receptor).
[0004] Positron emission tomography (PET), as a non-invasive imaging technique, supports drug discovery and development by providing valuable information about drug-target engagement, assessing drug occupancy, and monitoring treatment. In addition, PET can be used for neuroreceptor imaging in healthy subjects and diseased states (Nasrallah I, Dubroff, J An overview of PETneuroimaging, Seminars in nuclear medicine, 2013, 43, 449-61. Hou L, Rong J, HaiderA, et al. Positron Emission Tomography Imaging of the Endocannabinoid System: Opportunities and Challenges in Radiotracer Development, J. Med. Chem. 2021, 64, 1, 123–149). Alternatively, autoradiography can be used for in vitro neuroreceptor imaging on tissue sections obtained after death. In animal models, autoradiography can provide drug-target engagement information from in vitro readings. Containing GABA A PET imaging of the γ2 subunit of the receptor is well established, with many radiotracers routinely used in preclinical and clinical studies. Among them, the most prominent and important are [ 18 F] Flumazenil (or the carbon-11 version [ 11 C] flumazenil) and [ 11 C] Ro15-4513 (Kassenbrock A, Vasdev N, Liang SH, Selected PET Radioligands for IonChannel Linked Neuroreceptor Imaging: Focus on GABA, NMDA and nACh Receptors, Current Topics in Medicinal Chemistry, 2016, 16, 1830-1842). [ 18 Flumazenil can inhibit the production of GABA containing all α subunits A γ2 receptors are visualized, while [ 11 C] Ro15-4513 prefers GABA A Visualization of α5γ2 receptors. A γ2 receptors. Although selective GABA Aγ1 tracers (see, e.g., WO2021198124 and WO2021213952), but not targeting GABA in vivo A The compounds of the present invention exhibit increased affinity for the GABAA γ1 receptor and allow for in vivo imaging of the target. Summary of the invention
[0005] The radiolabeled compounds of the present invention are selective for GABA A γ1 receptor positive allosteric modulators (PAMs) can be used to visualize the receptor in vivo and in vitro, for example, by PET or autoradiography. The compounds of the present invention have high binding affinity and selectivity for subtypes containing γ1 (α5γ1, α2γ1, α1γ1) relative to subtypes containing γ2 (e.g., α1γ2, α2γ2, α3γ2, and α5γ2). Therefore, the compounds of the present invention can be used to make typical GABA A Receptor tracers unresolved for GABA A Visualization of γ1 receptors.
[0006] In a first aspect, the present invention provides a compound of formula (I) or formula (II)
[0007]
[0008] or a pharmaceutically acceptable salt thereof, wherein the compound comprises a radioactive label.
[0009] In another aspect, the invention provides a radiolabeled compound as described herein for use in the treatment of GABA A Used in γ1 occupancy studies.
[0010] In another aspect, the invention provides a radiolabeled compound as described herein for use in the treatment of GABA in mammals. A γ1 is used in diagnostic imaging. BRIEF DESCRIPTION OF THE DRAWINGS
[0011] Figure 1 Mouse coronal brain sections are shown. 3 H]-(I) and [ 3 H]-(II) in vitro autoradiography (see Example 5 for details).
[0012] Figure 2 Shown in baboon [ 11 C]-(I) and [ 11 C]-line graph of the regional time-activity curve (TAC) of (II) (specific reference to Example 6). DETAILED DESCRIPTION
[0013] definition
[0014] Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All features disclosed in this specification (including any accompanying claims, abstract and drawings) and / or all steps of any method or process disclosed thereby may be combined in any combination, except for combinations in which at least some of these features and / or steps are mutually exclusive. The invention is not limited to the details of any foregoing embodiments. The invention extends to any novel feature or any novel combination of features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel step or any novel combination of steps of any method or process disclosed thereby.
[0015] The term "pharmaceutical salt" refers to those salts that retain the biological effect and properties of free alkali or free acid, which are not undesirable in biology or other aspects. These salts are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc. (particularly hydrochloric acid) and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methylsulfonic acid, ethylsulfonic acid, p-toluenesulfonic acid, salicylic acid, N-acetylcysteine, etc. In addition, these salts can be prepared by adding inorganic bases or organic bases to free acids. Salts derived from inorganic bases include but are not limited to sodium, potassium, lithium, ammonium, calcium, magnesium salts, etc. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines (including naturally occurring substituted amines), cyclic amines, and basic ion exchange resins such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polyimine resins, and the like.
[0016] The term "mammal" includes humans, non-human primates (such as chimpanzees and other apes and monkey species), farm animals (such as cattle, horses, sheep, goats, and pigs), livestock (such as rabbits, dogs, and cats), laboratory animals (including rodents, such as rats, mice, and guinea pigs). In certain embodiments, the mammal is a human. The term "mammal" does not denote a particular age or sex.
[0017] The term "radioactive label" refers to radioactive isotopes such as hydrogen, carbon, nitrogen, oxygen, fluorine and chlorine. In some embodiments, the radioactive labels used in the context of the present invention are useful for PET imaging and / or autoradiography. Examples of isotopes that can be incorporated into the compounds of formula (I) and formula (II) as radioactive labels include, respectively3 H. 11 C. 14 C. 13 N. 15 O. 18 F and 36 Cl. Preferred radiolabeling is 3 H. 11 C. 13 N. 15 O and 18 F. A further preferred radiolabel is 3 H. 11 C and 18 F. A particularly preferred radiolabel is 3 H and 11 C.
[0018] Compounds of the present invention
[0019] In a first aspect, the present invention provides a compound of formula (I) or formula (II)
[0020]
[0021] or a pharmaceutically acceptable salt thereof, wherein the compound comprises a radioactive label.
[0022] The compounds of formula (I) or (II) of the present invention are radiolabeled by replacing one or more atoms with an isotope having a different atomic mass or mass number. Examples of isotopes that can be incorporated into the compounds of formula (I) and (II) include isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine and chlorine, respectively, such as but not limited to 3 H. 11 C. 14 C. 13 N. 15 O. 18 F and 36 Certain isotopically labeled compounds of Formula (I) and Formula (II) (e.g., those containing a radioactive isotope) are useful in drug and / or substrate tissue distribution studies. The radioactive isotope tritium (i.e. 3 H), carbon-11 (i.e. 11 C) and fluorine-18 (i.e. 18 F) are particularly useful for this purpose because they are easy to incorporate and detection means are readily available. For example, a compound of formula (I) may be enriched with 1, 2, 5, 10, 25, 50, 75, 90, 95 or 99% of a given isotope.
[0023] Using positron-emitting isotopes such as 11 C. 18 F. 15 O and 13N) substitutions can be used in positron emission tomography (PET) studies, for example to examine substrate receptor occupancy.
[0024] Use of negative beta emitting isotopes such as 3 H) Substitutions can be used in autoradiographic studies, for example to examine substrate receptor occupancy.
[0025] In one embodiment, the radioactive label is selected from 3 H. 11 C. 13 N. 15 O. 18 F and 36 Cl.
[0026] In a preferred embodiment, the radioactive label is selected from 11 C. 18 F and 3 H.
[0027] In a preferred embodiment, the radioactive label is selected from 11 C and 3 H.
[0028] In a particularly preferred embodiment, the radioactive label is 11 C.
[0029] In a particularly preferred embodiment, the radioactive label is 3 H.
[0030] In a particularly preferred embodiment, the radioactive label is 18 F.
[0031] In one embodiment, the compound of formula (I) or formula (II) of the present invention is selected from the group consisting of:
[0032] as well as
[0033]
[0034] or a pharmaceutically acceptable salt thereof.
[0035] In a preferred embodiment, the compound of formula (I) or formula (II) of the present invention is
[0036]
[0037] or a pharmaceutically acceptable salt thereof.
[0038] In a preferred embodiment, the compound of formula (I) or formula (II) of the present invention is
[0039]
[0040] or a pharmaceutically acceptable salt thereof.
[0041] In a preferred embodiment, the compound of formula (I) or formula (II) of the present invention is
[0042]
[0043] or a pharmaceutically acceptable salt thereof.
[0044] In a preferred embodiment, the compound of formula (I) or formula (II) of the present invention is
[0045]
[0046] or a pharmaceutically acceptable salt thereof.
[0047] Use of the Compounds of the Invention
[0048] The radiolabeled compounds of the present invention are effective GABA A γ1 positive allosteric modulators (PAMs), which can be used as, for example, GABA A PET tracer of γ1 receptors to validate therapeutic GABA A Target engagement of γ1 modulators, and studying GABA A Function of the gamma 1 receptor in normal and disease conditions.
[0049] Therefore, in one aspect, the present invention provides a method for treating GABA in mammals. A γ1 A method of performing diagnostic imaging, the method comprising:
[0050] (a) administering to the mammal a detectable amount of a radiolabeled compound described herein or a pharmaceutically acceptable salt thereof; and
[0051] (b) Detection and GABA A The radiolabeled compound when γ1 associated.
[0052] In a preferred embodiment, the diagnostic imaging is diagnostic imaging of the brain.
[0053] In preferred embodiments, said detecting is via autoradiography and / or PET.
[0054] In preferred embodiments, said detecting is detection via autoradiography.
[0055] In a preferred embodiment, the detecting is performed via PET.
[0056] In another aspect, the present invention provides a radiolabeled compound as described herein, or a pharmaceutically acceptable salt thereof, for use in a method of diagnostic imaging as described herein.
[0057] In another aspect, the present invention provides the use of a radiolabeled compound as described herein, or a pharmaceutically acceptable salt thereof, in a method of diagnostic imaging as described herein.
[0058] In another aspect, the present invention provides a radiolabeled compound as described herein or a pharmaceutically acceptable salt thereof for use in GABA A γ1 occupancy studies. For example, such occupancy studies can be performed as described in Scientific Reports (2021), 11(1), 7700.
[0059] In another aspect, the present invention provides radiolabeled compounds described herein in GABA A Uses in gamma-1 occupancy studies.
[0060] In one embodiment, the GABA A γ1 occupancy studies include GABA A γ1 is contacted with a radiolabeled compound disclosed herein or a pharmaceutically acceptable salt thereof.
[0061] In another aspect, the present invention provides a method for studying GABA A A method for increasing the occupancy of a GABA γ1 receptor, the method comprising: A The gamma 1 receptor is contacted with a radiolabeled compound described herein.
[0062] In one embodiment, the GABA A The γ1 occupancy studies were in vitro occupancy studies.
[0063] Examples
[0064] The present invention will be more fully understood by reference to the following examples. However, the claims should not be interpreted as being limited to the scope of the examples.
[0065] If not stated otherwise, all reaction examples and intermediates were prepared under argon atmosphere.
[0066] Building block synthesis
[0067] The building blocks can be produced according to the following synthetic procedures.
[0068] Structural unit A
[0069] 6,7-Dichloro-5-(2-fluoro-5-methoxy-phenyl)-1,3-dihydro-1,4-benzodiazepine -2-Keto
[0070]
[0071] a) 5-Chloro-2-methyl-3,1-benzoxazin-4-one
[0072] A solution of 2-amino-6-chlorobenzoic acid (15.0 g, 87.4 mmol) in acetic anhydride (200 mL) was stirred at 140° C. for 2 h. The reaction solution was concentrated in vacuo. The residue was suspended in acetonitrile, the solid was filtered and the filter cake was dried in vacuo to give the title compound (11.3 g, 66%) as a white solid. 1 H NMR (400MHz, CDCl3) δppm 2.47 (3H, s) 7.47 (1H, dd, J = 8.1, 0.9 Hz) 7.53 (1H, dd, J = 7.9, 1.0 Hz) 7.67 (1H, dd, J = 8.1, 8.0 Hz).
[0073] b) N-[3-Chloro-2-(2-fluoro-5-methoxy-benzoyl)phenyl]acetamide
[0074] To a solution of 2-bromo-1-fluoro-4-methoxybenzene (5.45 g, 26.6 mmol) in THF (200 mL) was added n-butyl lithium (2.5 m in hexanes, 12.8 mL, 31.9 mmol) at -78 °C. After stirring for 1 h, 5-chloro-2-methyl-3,1-benzoxazine-4-one (5.20 g, 26.6 mmol) was added to the mixture and stirring was continued for another 1 h at -78 °C. The mixture was quenched with saturated aqueous NH4Cl solution and extracted with ethyl acetate. The organic layer was dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified by preparative HPLC (Phenomenex luna C18, 10 μm, 250x50 mm, water / acetonitrile solution containing 0.05% HCl) to give the title compound (3.63 g, 42%) as a light yellow solid. MS: 322.1 ([{ 35 Cl}M+H] + ),324.1([{ 37 Cl}M+H] + ),ESI pos.
[0075] c) (2-amino-6-chloro-phenyl)-(2-fluoro-5-methoxy-phenyl)methanone
[0076] To a solution of N-[3-chloro-2-(2-fluoro-5-methoxy-benzoyl)phenyl]acetamide (4.00 g, 12.4 mmol) in ethanol (50 mL) was added aqueous HCl (37%, 53.3 mL, 640 mmol). The mixture was stirred at 100 ° C for 2 h and then concentrated in vacuo. The residue was dissolved in DCM and washed with saturated aqueous NaHCO3 and water. The organic layer was dried (Na2SO4), filtered and concentrated in vacuo to give the title compound as an off-white solid (2.87 g, 83%). MS: 280.0 ([{ 35 Cl}M+H] + ),282.0([{ 37 Cl}M+H] + ),ESI pos.
[0077] d) (6-amino-2,3-dichloro-phenyl)-(2-fluoro-5-methoxy-phenyl)methanone
[0078] A solution of (2-amino-6-chloro-phenyl)-(2-fluoro-5-methoxy-phenyl)methanone (1.00 g, 3.58 mmol) and N-chlorosuccinimide (430 mg, 3.22 mmol) in DMF (20 mL) was stirred at 0 ° C for 2 h. The mixture was quenched with water and extracted with DCM. The organic layer was dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified by preparative HPLC (Phenomenex Synergi C18, 10 μm, 150x25 mm, water / acetonitrile solution containing 0.1% trifluoroacetic acid) to give the title compound (367 mg, 33%) as a light yellow solid. MS: 313.9 ([{ 35 Cl, 35 Cl}M+H] + ),315.9([{ 35 Cl, 37 Cl}M+H] + ),ESI pos.
[0079] e) 6,7-Dichloro-5-(2-fluoro-5-methoxy-phenyl)-1,3-dihydro-1,4-benzodiazepine -2-Keto
[0080] At 100 ° C, glycine ethyl ester hydrochloride (2.89 g, 20.7 mmol) and (6-amino-2,3-dichloro-phenyl)-(2-fluoro-5-methoxy-phenyl)methanone (650 mg, 2.07 mmol) were stirred in a solution of pyridine (30 mL) for 16 h. The mixture was concentrated in vacuo. The residue was purified by preparative HPLC (Phenomenex Synergi C18, 10 μm, 150x25 mm, water / acetonitrile solution containing 0.1% trifluoroacetic acid) to give the title compound (280 mg, 38%) as a yellow solid. MS: 353.0 ([{ 35 Cl, 35 Cl}M+H] + ),355.0([{ 35 Cl, 37 Cl}M+H] + ),ESI pos.
[0081] Structural unit B6-Chloro-5-(2-fluoro-5-methoxy-phenyl)-7-methyl-1,3-dihydro-1,4-benzodiazepine -2-Keto
[0082]
[0083] a)(6-Amino-3-bromo-2-chloro-phenyl)-(2-fluoro-5-methoxy-phenyl)methanone
[0084] Analogously to the experiment of building block A d, (2-amino-6-chloro-phenyl)-(2-fluoro-5-methoxy-phenyl)methanone (building block A c) was converted to the title compound (1.63 g, 64%) using N-bromosuccinimide instead of N-chlorosuccinimide. The title compound was obtained as a light yellow solid. MS: 357.9 ([{ 79 Br, 35 Cl}M+H] + ),359.9([{ 81 Br, 35 Cl or 79 Br, 37 Cl}M+H] + ),ESI pos.
[0085] b) 7-Bromo-6-chloro-5-(2-fluoro-5-methoxy-phenyl)-1,3-dihydro-1,4-benzodiazepine -2-Keto
[0086] Analogously to the experiment with building block A e, (6-amino-3-bromo-2-chloro-phenyl)-(2-fluoro-5-methoxy-phenyl)methanone was converted into the title compound (1.63 g, 64%) as a pale yellow solid (860 mg, 38%), which was obtained as a pale yellow solid. MS: 396.9 ([{ 79 Br, 35 Cl}M+H] + ),398.9([{ 81 Br, 35 Cl or 79 Br, 37 Cl}M+H] + ),ESIpos.
[0087] c) 6-Chloro-5-(2-fluoro-5-methoxy-phenyl)-7-methyl-1,3-dihydro-1,4-benzodiazepine -2-Keto
[0088] 7-Bromo-6-chloro-5-(2-fluoro-5-methoxyphenyl)-1,3-dihydro-1,4-benzodiazepine A solution of -2-ketone (600 mg, 1.51 mmol), methylboronic acid (117 mg, 1.96 mmol), potassium phosphate (641 mg, 3.02 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (1.10 g, 1.51 mmol) in DMF (12 mL) was stirred at 80 ° C under nitrogen for 6 h. The reactant was diluted with methanol, filtered through a diatomaceous earth plug and the filtrate was concentrated in vacuo. The residue was treated with water and extracted with ethyl acetate. The organic layer was dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified by preparative HPLC (Phenomenex Synergi C18, 10 μm, 150x25 mm, water / acetonitrile solution containing 0.1% trifluoroacetic acid) to give the title compound (230 mg, 45%) in light brown. MS: 333.1 ([{ 79 Br, 35 Cl}M+H] + ),335.1([{ 81 Br, 35 Cl or 79 Br, 37 Cl}M+H] + ),ESI pos.
[0089] 11 C radiolabeled precursor 1
[0090] 5-[5-[tert-Butyl(dimethyl)silyl]oxy-2-fluoro-phenyl]-6,7-dichloro-1,3-dihydro-1,4-benzodiazepine -2-Keto
[0091]
[0092] a) tert-Butyl N-[3,4-dichloro-2-[(2-fluoro-5-methoxy-phenyl)-hydroxy-methyl]phenyl]carbamate
[0093] At -90 ° C, tert-butyl lithium was added dropwise to a solution of tert-butyl N-(3,4-dichlorophenyl)carbamate (5.82 g, 22.2 mmol) in THF (64 mL) from a dry ice-cooled dropping funnel, and 1.7 ml and the resulting mixture in pentane (28.7 ml, 48.8 mmol) were stirred for another 0.5 h at -85 ° C. Then a solution of 2-fluoro-5-methoxybenzaldehyde (3.76 g, 24.4 mmol) in THF (16 ml) was added dropwise from a dry ice-cooled dropping funnel at -85 ° C to -90 ° C. After stirring for another 0.5 h at -90 to -85 ° C, the mixture was heated to -65 ° C, and then quenched by dropping a saturated NH4Cl aqueous solution. The mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The residue was suspended in DCM, the solid was filtered and dried under high vacuum to give the title compound as a white solid (4.29 g, 46%). MS: 414.2 ([{ 35 Cl, 35 Cl}MH]-),416.2([{ 35 Cl, 37 Cl}MH]-),ESI neg.
[0094] b) tert-Butyl (3,4-dichloro-2-(2-fluoro-5-methoxybenzoyl)phenyl)carbamate
[0095] To a suspension of tert-butyl N-[3,4-dichloro-2-[(2-fluoro-5-methoxy-phenyl)-hydroxy-methyl]phenyl]carbamate (9.58 g, 23 mmol) in DCM (95 ml) at 22°C was added water (95 ml), potassium bromide (383 mg, 3.22 mmol) and sodium bicarbonate (773 mg, 9.21 mmol) to give two layers, which were cooled to 0°C. TEMPO (75.5 mg, 483 μmol) was then added and sodium hypochlorite (21.4 g, 17.8 ml, 34.5 mmol) was added dropwise under vigorous stirring (over 1 h) while keeping the internal temperature below 2°C. The mixture was warmed to 22°C and extracted with DCM (3×100 ml). The organic layer was washed with water (1×100 ml) and half-saturated NaCl (1×100 ml), dried over Na2SO4, filtered and evaporated. The residue (light brown foam) was treated with EtOAc (50 ml) to give a precipitate, the suspension was stirred for 30 minutes, and the solid was filtered off, washed with EtOAc (2×20 ml) and dried to give the product as a white solid (5.602 g, 59%). The filtrate was concentrated, adsorbed on Isolute adsorbent and purified by flash chromatography (silica gel, 330 g, adsorbed on Isolute HM-N, EtOAc in heptane 5% to 10%) to give additional product as a white solid (3.00 g, 31%). 412.2 ([{ 35 Cl, 35 Cl}MH]-),414.2([{ 35 Cl, 37 Cl}MH]-),ESI neg.
[0096] c) (6-amino-2,3-dichloro-phenyl)-(2-fluoro-5-methoxy-phenyl)methanone
[0097] To a solution of tert-butyl N-[3,4-dichloro-2-[(2-fluoro-5-methoxy-phenyl)-hydroxymethyl]phenyl]carbamate (8.60 g, 20.8 mmol) in DCM (200 mL) was added trifluoroacetic acid (47.3 g, 415 mmol) at 22 ° C, and the mixture was stirred at 22 ° C for 2 h. The solution was concentrated in vacuo. The residue (combined with another batch -17.9 mmol scale) was treated with saturated aqueous NaHCO3 and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, filtered and concentrated in vacuo to give the title compound (11.0 g, 90%) as a yellow solid. MS: 314.0 ([{ 35 Cl, 35 Cl}M+H] + ),316.0([{ 35 Cl, 37 Cl}M+H]+ ),ESI pos.
[0098] d) 6,7-Dichloro-5-(2-fluoro-5-methoxy-phenyl)-1,3-dihydro-1,4-benzodiazepine -2-Keto (Structural unit A, alternative synthesis)
[0099] A solution of (6-amino-2,3-dichloro-phenyl)-(2-fluoro-5-methoxy-phenyl)methanone (8.35 g, 26.6 mmol) in pyridine (165 mL) was heated to 90 ° C, then glycine ethyl ester hydrochloride (26.0 g, 186 mmol) was added all at once, and the resulting mixture was stirred at 110 ° C for 4 h. The mixture was cooled to 90 ° C, and then glycine ethyl ester hydrochloride (14.8 g, 106 mmol) was further added, and stirring was continued at 110 ° C for 16 h. The mixture was cooled to room temperature and concentrated in vacuo. The residue was treated with saturated NaHCO3 aqueous solution and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by flash column chromatography (silica, heptane containing 10% to 100% ethyl acetate) to give the title compound (5.47 g, 58%) as a yellow solid. MS: 353.0 ([{ 35 Cl, 35 Cl}M+H] + ),355.0([{ 35 Cl, 37 Cl}M+H] + ),ESI pos.
[0100] e) 6,7-Dichloro-5-(2-fluoro-5-hydroxy-phenyl)-1,3-dihydro-1,4-benzodiazepine -2-Keto
[0101] At -65 °C, 6,7-dichloro-5-(2-fluoro-5-methoxy-phenyl)-1,3-dihydro-1,4-benzodiazepine was added. -2-ketone (500mg, 1.42mmol) was added dropwise to a light yellow solution of boron tribromide (1.77g, 7.08mmol) in DCM (15mL). The mixture was heated to -20°C and stirred for 0.5h. The mixture was quenched with a half-saturated aqueous solution of NaHCO3 and extracted with DCM. The organic layer was washed with a half-saturated aqueous solution of NaHCO3, dried over sodium sulfate, filtered and concentrated in vacuo. The aqueous layer was extracted again with ethyl acetate, the organic layer was dried over sodium sulfate, filtered and concentrated in vacuo. The two residues were combined and purified by flash column chromatography (silica, heptane containing 10% to 100% ethyl acetate), and then crystallized from MTBE / heptane to give the title compound (220mg, 46%) as a light yellow solid. MS: 339.0 ([{35 Cl, 35 Cl}M+H] + ),341.0([{ 35 Cl, 37 Cl}M+H] + ),ESI pos.
[0102] f) 5-[5-[tert-butyl(dimethyl)silyl]oxy-2-fluoro-phenyl]-6,7-dichloro-1,3-dihydro-1,4- Benzodiazepines -2-Keto
[0103] At 22°C, 6,7-dichloro-5-(2-fluoro-5-hydroxy-phenyl)-1,3-dihydro-1,4-benzodiazepine was added. To a solution of -2-ketone (175 mg, 0.516 mmol) in DMF (1.75 mL) was added imidazole (77.3 mg, 1.14 mmol), followed by tert-butyldimethylsilyl chloride (85.5 mg, 0.568 mmol) and the resulting mixture was stirred at 22 ° C for 0.5 h. The mixture was concentrated in vacuo. The residue was treated with an aqueous NaOH solution (0.1 m) and extracted with ethyl acetate. The organic layer was washed successively with an aqueous NaOH solution (0.1 m) and brine, dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by flash column chromatography (silica, heptane containing 0% to 30% ethyl acetate) and then crystallized from ethyl acetate / heptane to give the title compound (122 mg, 52%) as a white solid. MS: 453.2 ([{ 35 Cl, 35 Cl}M+H] + ),455.1([{ 35 Cl, 37 Cl}M+H] + ),ESI pos.
[0104] 11 C radiolabeled precursor 2
[0105] 5-[5-[tert-Butyl(dimethyl)silyl]oxy-2-fluoro-phenyl]-6-chloro-7-methyl-1,3-dihydro-1,4-benzodiazepine -2-Keto
[0106]
[0107] a) 6-Chloro-5-(2-fluoro-5-hydroxy-phenyl)-7-methyl-1,3-dihydro-1,4-benzodiazepine -2-Keto
[0108] At -65 °C, 6-chloro-5-(2-fluoro-5-methoxy-phenyl)-7-methyl-1,3-dihydro-1,4-benzodiazepine was added. To a solution of -2-ketone (500 mg, 1.50 mmol) in DCM (15 mL) was added boron tribromide (1.88 g, 7.51 mmol). The mixture was stirred at -60 ° C for 0.5 h. The mixture was then heated to -20 ° C and stirred for 0.5 h. The mixture was quenched with saturated NaHCO3 aqueous solution and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by flash column chromatography (silica, petroleum ether containing 10% to 100% ethyl acetate) and then crystallized from ethyl acetate / heptane to give the title compound (177 mg, 37%) as a light yellow solid. MS: 319.1 ([{ 79 Br, 35 Cl}M+H] + ),321.1([{ 81 Br, 35 Cl or 79 Br, 37 Cl}M+H] + ),ESI pos.
[0109] b) 5-[5-[tert-butyl(dimethyl)silyl]oxy-2-fluoro-phenyl]-6-chloro-7-methyl-1,3-dihydro- 1,4-Benzodiazepine -2-Keto
[0110] At 22°C, 6-chloro-5-(2-fluoro-5-hydroxy-phenyl)-7-methyl-1,3-dihydro-1,4-benzodiazepine was added. To a solution of -2-ketone (184 mg, 0.577 mol) in DMF (1.8 mL) was added imidazole (86.5 mg, 1.27 mmol), followed by tert-butyldimethylsilyl chloride (95.7 mg, 0.635 mmol) and the mixture was stirred at 22 ° C for 1 h. The mixture was concentrated in vacuo, treated with an aqueous NaOH solution (0.1 m), and extracted with ethyl acetate. The organic layer was washed with an aqueous NaOH solution (0.1 m) and brine, dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by flash column chromatography (silica, petroleum ether containing 0% to 45% ethyl acetate) and then crystallized from ethyl acetate / heptane to give the title compound (110 mg, 44%) as a white solid. MS: 433.2 ([{ 79 Br, 35 Cl}M+H] + ),435.2([{ 81 Br, 35 Cl or 79 Br, 37 Cl}M+H] + ),ESI pos.
[0111] Examples
[0112] Example 1
[0113] 6,7-Dichloro-5-(2-fluoro-5-hydroxy-phenyl)-1-methyl-3H-1,4-benzodiazepine -2-one(I)
[0114]
[0115] a) 6,7-Dichloro-5-(2-fluoro-5-methoxy-phenyl)-1-methyl-3H-1,4-benzodiazepine -2-Keto
[0116] At 25°C, 6,7-dichloro-5-(2-fluoro-5-methoxy-phenyl)-1,3-dihydro-1,4-benzodiazepine -2-ketone (structural unit A, 120 mg, 0.340 mmol), iodomethane (1.00 g, 7.05 mmol) and potassium carbonate (70 mg, 0.51 mmol) in DMF (3 mL) were stirred for 0.5 h. The reaction was quenched with water and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by preparative HPLC (Phenomenex Synergi C18, 10 μm, 150x25 mm, water / acetonitrile solution containing 0.1% trifluoroacetic acid) to give the title compound (114 mg, 91%) as a white solid. MS: 367.1 ([{ 35 Cl, 35 Cl}M+H] + ),369.1([{ 35 Cl, 37 Cl}M+H] + ),ESI pos.
[0117] b) 6,7-Dichloro-5-(2-fluoro-5-hydroxy-phenyl)-1-methyl-3H-1,4-benzodiazepine -2-Keto
[0118] At 0°C, 6.7-dichloro-5-(2-fluoro-5-methoxy-phenyl)-1-methyl-3H-1,4-benzodiazepine was added. To a solution of -2-ketone (80 mg, 0.22 mmol) in DCM (9 mL) was added boron tribromide (273 mg, 1.09 mmol) dropwise. The reaction mixture was stirred at 0 ° C for 1 h, then heated to room temperature and stirred for another 5 h. The reaction was quenched with ice water and extracted with DCM. The organic layer was dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by preparative HPLC (Phenomenex Synergi C18, 10 μm, 150x25mm, water / acetonitrile solution containing 0.225% formic acid) to give the title compound (59 mg, 77%) as a white solid. MS: 353.1 ([{ 35 Cl, 35 Cl}M+H] + ),355.1([{ 35 Cl, 37 Cl}M+H] + ),ESI pos.
[0119] Example 2
[0120] 6-Chloro-5-(2-fluoro-5-hydroxy-phenyl)-1,7-dimethyl-3H-1,4-benzodiazepine -2-Keto(II)
[0121]
[0122] a) 6-Chloro-5-(2-fluoro-5-methoxy-phenyl)-1,7-dimethyl-3H-1,4-benzodiazepine -2-Keto
[0123] Similar to the experiment of Example 1a, 6-chloro-5-(2-fluoro-5-methoxy-phenyl)-7-methyl-1,3-dihydro-1,4-benzodiazepine -2-ketone (structural unit B) was converted to the title compound (76 mg, 36%), which was obtained as a yellow solid. MS: 347.1 ([{ 35 Cl}M+H] + ),349.1([{ 37 Cl}M+H] + ),ESI pos.
[0124] b) 6-Chloro-5-(2-fluoro-5-hydroxy-phenyl)-1,7-dimethyl-3H-1,4-benzodiazepine -2-Keto
[0125] Similar to the experiment of Example 1b, 6-chloro-5-(2-fluoro-5-methoxy-phenyl)-1,7-dimethyl-3H-1,4-benzodiazepine -2-ketone was converted to the title compound (72 mg, 83%), which was obtained as an off-white solid. MS: 333.0 ([{ 35 Cl}M+H] + ),335.0([{ 37 Cl}M+H] + ),ESI pos.
[0126] Example 3 H]1
[0127] 6,7-Dichloro-5-(2-fluoro-5-hydroxy-phenyl)-1-([ 3 H3]methyl)-3H-1,4-benzodiazepine -2-Keto
[0128]
[0129] a) 6,7-Dichloro-5-(2-fluoro-5-methoxy-phenyl)-1-([ 3 H3]methyl)-3H-1,4-benzodiazepine -2- ketone Towards[ 3 H3] 6,7-dichloro-5-(2-fluoro-5-methoxy-phenyl)-1,3-dihydro-1,4-benzodiazepine was added to methyl p-nitrobenzenesulfonate (1.85 GBq, 50 mCi, 0.61 μmol). -2-ketone (structural unit A) (443 μg, 1.25 μmol, 2.0 equivalents) in THF (120 μL) solution. Then add 0.5M solution of sodium tert-butoxide (6.3 μL, 3.1 μmol, 5.0 equivalents) in THF, and the reaction mixture is stirred at room temperature for 2h. Water (20 μL) is added to quench the reaction. The solvent is evaporated under an argon stream, and the remaining solid is dissolved in MeCN / H2O 1:1 (180 μL). The crude product was purified by HPLC (Sunfire C18 OBD, 4.6 x 250 mm, MeCN[A] / H2O+5% MeCN[B], gradient: 1-18 min, [A]:[B] 10:90 to 90:10; 18.0-18.1, 90:10 to 95:5; 21.0 to 21.1, 95:5 to 10:90, run time 24 min, flow rate 1 mL / min, 236 nm, oven temperature 40°C; 5 injections). The pure fractions were combined, frozen and lyophilized under vacuum for 1.5 h. The product was used directly in the next step without further characterization.
[0130] b) 6,7-Dichloro-5-(2-fluoro-5-hydroxy-phenyl)-1-([ 3 H3]methyl)-3H-1,4-benzodiazepine -2-Keto
[0131] 6,7-dichloro-5-(2-fluoro-5-methoxy-phenyl)-1-([ 3 H3]methyl)-3H-1,4-benzodiazepine -2-ketone (predicted from previous experiments: 131μg, 0.35μmol, 1 equivalent, 28mCi) was dissolved in dichloromethane (0.5mL) and transferred to a 1mL Alltech tube. The solvent was evaporated under an argon stream. The operation was repeated three times using a total of 1.5mL of dichloromethane. The residue was dissolved in dichloromethane (ultra-dry, through molecular sieves, 0.15mL) and treated with 1M boron tribromide solution (5.3μL, 5.3μmol, 15 equivalents). The tube was sealed with a polytetrafluoroethylene sealed plastic cap. The solution turned yellow and was stirred at 40°C (oil bath temperature) for 4h. Radioactive HPLC analysis showed that the starting material was almost completely consumed. At room temperature, water (20μL) was added to quench the reaction. The solvent was evaporated under an argon stream, and the remaining solid was dissolved in MeCN / H2O 1:1 (150μL). The crude product was purified by HPLC (Sunfire C18 OBD, 4.6 x 250 mm, MeCN[A] / H2O+5% MeCN[B], gradient: 1-18 min, [A]:[B] 10:90 to 90:10; 18.0-18.1, 90:10 to 95:5; 21.0 to 21.1, 95:5 to 10:90, run time 24 min, flow rate 1 mL / min, 236 nm, oven temperature 40°C; 5 injections). The pure fractions were combined, frozen and lyophilized under vacuum for 2 h. The pure tritium-labeled compound (337 MBq, 9.1 mCi) was dissolved and stored in ethanol (10 mL). The radiochemical purity measured by radio-HPLC was 96%, and the specific activity measured by mass spectrometry (MS) was 3.0 TBq / mmol (81 Ci / mmol). The identity of the labeled compound was confirmed by HPLC (by co-injection with an unlabeled reference standard) and MS. MS: m / z = 353.0 [M (H) + H] + (3%),355.0[M( 3 H)+H] + (0%),357.0[M( 3 H2)+H] + (6%),359.0.1[M( 3 H3)+H] + (90%).
[0132] Example 3 H]2
[0133] 6-Chloro-5-(2-fluoro-5-hydroxy-phenyl)-7-methyl-1-([ 3H3]methyl)-3H-1,4-benzodiazepine -2-Keto
[0134]
[0135] a) 6-Chloro-5-(2-fluoro-5-methoxy-phenyl)-7-methyl-1-([ 3 H3]methyl)-3H-1,4-benzodiazepine -2-Keto
[0136] Towards[ 3 H3] 6-chloro-5-(2-fluoro-5-methoxy-phenyl)-7-methyl-1,3-dihydro-1,4-benzodiazepine was added to methyl p-nitrobenzenesulfonate (1.85 GBq, 50 mCi, 0.61 μmol). -2-ketone (structural unit B) (417 μg, 1.25 μmol, 2.0 equivalents) in THF (120 μL) solution. Then add 0.5M solution of sodium tert-butoxide (6.3 μL, 3.1 μmol, 5 equivalents) in THF, and stir the reaction mixture at room temperature for 130 min. Add water (20 μl) to quench the reaction. The solvent is evaporated under an argon stream, and the remaining solid is dissolved in MeCN / H2O 1:1 (160 μL). The crude product was purified by HPLC (Sunfire C18 OBD, 4.6 x 250 mm, MeCN[A] / H2O+5% MeCN[B], gradient: 1-18 min, [A]:[B] 10:90 to 90:10; 18.0-18.1, 90:10 to 95:5; 21.0 to 21.1, 95:5 to 10:90, run time 24 min, flow rate 1 mL / min, 236 nm, oven temperature 40°C; 5 injections). The pure fractions were combined, frozen and lyophilized under vacuum for 2 h. The pure tritium-labeled compound (1040 MBq, 28.1 mCi) was dissolved and stored in ethanol (10 mL) until further use. The radiochemical purity measured by radio-HPLC was >99%.
[0137] b) 6-Chloro-5-(2-fluoro-5-hydroxy-phenyl)-7-methyl-1-([ 3 H3]methyl)-3H-1,4-benzodiazepine - 2-Keto
[0138] At 40°C, 6-chloro-5-(2-fluoro-5-methoxy-phenyl)-7-methyl-1-([ 3 H3]methyl)-3H-1,4-benzodiazepine -2-ketone (124μg, 0.351μmol, 1 equivalent, 28.1mCi) solution in ethanol (10mL) was concentrated to dryness under rotary evaporation. The residue was dissolved in dichloromethane (0.5mL) and transferred to 1mL Alltech tube. The solvent was evaporated under argon flow. The operation was repeated three times using a total of 1.5mL of dichloromethane. The residue was dissolved in dichloromethane (ultra-dry, through molecular sieves, 0.15mL) and treated with 1M boron tribromide solution (3.5μL, 3.5μmol, 10 equivalents). The tube was sealed with a polytetrafluoroethylene sealed plastic cap. The solution turned yellow and was stirred at 40°C (oil bath temperature) for 3h. Radioactive HPLC analysis showed that the starting material was almost completely consumed. At room temperature, water (20μL) was added to quench the reaction. The solvent was evaporated under an argon stream, and the remaining solid was dissolved in MeCN / H2O 1:1 (200μL). The crude product was purified by HPLC (Sunfire C18 OBD, 4.6 x 250 mm, MeCN[A] / H2O+5% MeCN[B], gradient: 1-18 min, [A]:[B] 10:90 to 90:10; 18.0-18.1, 90:10 to 95:5; 21.0 to 21.1, 95:5 to 10:90, run time 24 min, flow rate 1 mL / min, 236 nm, oven temperature 40°C; 5 injections). The pure fractions were combined, frozen and lyophilized under vacuum for 2 h. The pure tritium-labeled compound (410.7 MBq, 11.1 mCi) was dissolved and stored in ethanol (10 mL). The radiochemical purity measured by radio-HPLC was 97%, and the specific activity measured by mass spectrometry (MS) was 3.1 TBq / mmol (83 Ci / mmol). The identity of the labeled compound was confirmed by HPLC (by co-injection with an unlabeled reference standard) and MS. MS: m / z = 333.1 [M (H) + H] + (2%),335.1[M( 3 H)+H] + (0%),337.1[M( 3 H2)+H] + (7%),339.1[M( 3 H3)+H] + (91%).
[0139] Example 11 C]1
[0140] [ 11 C] 6,7-Dichloro-5-(2-fluoro-5-hydroxy-phenyl)-1-methyl-3H-1,4-benzodiazepine -2-Keto
[0141]
[0142] The radiochemical synthesis of the tracer was carried out by 11 C] 6-Chloro-5-(2-fluoro-5-hydroxy-phenyl)-1,7-dimethyl-3H-1,4-benzodiazepine -2-ketone (Example [ 11 C] 2), except that the preparative mobile phase flow rate was 15 mL / min. The preparative retention time of the radiotracer was 6.1 min. The quality control of the radiotracer was completed in the same manner as below, except that the mobile phase was 35:65 acetonitrile (MeCN) / TEA buffer (pH 7.2) and the UV wavelength monitored was 254 nm. Comparable radiochemical purity and chemical purity, specific activity (molar activity) and chemical characterization results were obtained.
[0143] Example 11 C]2
[0144] [ 11 C] 6-Chloro-5-(2-fluoro-5-hydroxy-phenyl)-1,7-dimethyl-3H-1,4-benzodiazepine -2-Keto
[0145]
[0146] The standard CO2 gas target of the General Electric (GE) Medical Systems (GEMS, Uppsala, Sweden) PETTrace cyclotron was filled with high-purity nitrogen containing 0.5% oxygen. The target was irradiated with a 60 μA proton beam for 25 min to produce approximately 2-3 Ci (74-111 GBq) of [ 11 C] carbon dioxide. The radioactive gas is transferred to the GEFXMeI module, which synthesizes 11 CH3I, then helium 11 The CH3I was transferred to an appropriate hot cell for radiosynthesis. The precursor 5-[5-[tert-butyl(dimethyl)silyl]oxy-2-fluoro-phenyl]-6-chloro-7-methyl-1,3-dihydro-1,4-benzodiazepine was added. -2-ketone (1 ± 0.3 mg) was dissolved in 200 μL dimethylformamide (DMF) and added to a vial containing potassium carbonate (1 ± 0.3 mg), which was then sealed. Prior to the end of bombardment (EOB), the vial was placed in a lead-lined synthesis cell. 11CHI after, the bottle is heated (80 ℃) 3min.Hydrochloric acid (1mL) is added in the reaction mixture, and the bottle is heated (80 ℃) 1min.The reaction solution is diluted with 1mL 30% acetonitrile: 70% aqueous buffer (57mM TEA is adjusted to pH 7.2 with ortho-phosphoric acid) and injected into a semi-preparative HPLC column (XBridge C-18, 10 μm, 10mm × 150mm), eluted with 30% acetonitrile: 70% aqueous buffer (57mM TEA is adjusted to pH 7.2 with ortho-phosphoric acid) at 10mL / min, wherein the radioactive content and UV (254nm) of the effluent are monitored. The product peak (t R =6.7min, k'=5.7) were collected in 50 mL of water. The product solution was eluted onto a conditioned Waters C18 SepPak Plus (Waters Corp.) and the SepPak was washed with Waters HPLC water (10 mL). The radiotracer product was eluted from the SepPak with absolute ethanol (1 mL) and then with sterile saline (10 mL) through a 0.2 μm sterile Millipore FG filter (25 mm) into a sterile product vial pre-filled with sterile saline (4 mL). An aliquot was removed from the final product vial for quality control analysis.
[0147] Analytical HPLC was performed using an XBridge C-18 column (3.5 μm, 4.6 mm×100 mm) eluted with 30:70 acetonitrile (MeCN) / TEA buffer (pH 7.2), eluted at 2 mL / min and monitored at 236 nm to determine radiochemical and chemical purity, specific activity (molar activity) and chemical identity. The final radiotracer product exhibited a radiochemical purity greater than 95%, with an average yield of more than 100 mCi of the product co-eluted with the authentic cold reference. The average specific activity (molar activity) was greater than 10 Ci per micromole (370 GBq per micromole).
[0148] Example 3 - Assay Procedure
[0149] For GABA containing γ1 A Membrane preparation and binding assay of isoforms
[0150] The compounds of formula (I) and formula (II) (see Examples 1 and 2 above) have an effect on GABA-containing A The affinity of the receptor for the γ1 subunit is determined by targeting [ 3H]RO7239181 (67.3 Ci / mmol; Roche; described, for example, in WO2021198124) was measured by competition with membrane binding from HEK293F cells (ThermoFisherR79007) expressing human (transiently transfected) receptors of the composition α5β2γ1, α2β2γ1, α1β2γ1. In order to achieve better protein expression of receptors containing the α2 subunit, human GABA A The 28 amino acid signal peptide (Met1 to Ala28) of the α2 subunit was replaced by human GABA A The α5 subunit has a signal peptide of 31 amino acids (Met1 to Ser31).
[0151] Different GABA expressions AThe precipitate harvested from HEK293F cells of the receptor subtype was resuspended in mannitol buffer (mannitol 0.29M, triethylamine 10mM, acetic acid 10mM, EDTA 1mM plus protease inhibitors (20 tablets Complete, Roche Diagnostics catalog number 05 056 489 001, per liter) at pH 7.2 to 7.4, washed twice, and then resuspended in the same buffer at a dilution ratio of 1:10 to 1:15. Cell disruption was performed by stirring the suspension at 435psi for 15 minutes in a Parr container #4637, and then the suspension was centrifuged at 1000xg for 15 minutes at 4°C (Beckman AvantiJ-HC; rotor JS-4.2). The supernatant (S1) was transferred to a 2l Schott flask and the precipitate (P1) was resuspended to 175ml with mannitol buffer. The resuspended pellet was transferred to a 250 ml Corning centrifuge beaker and centrifuged at 1500 x g for 10 minutes at 4°C (Beckman Avanti J-HC; rotor JS-4.2). The supernatant (S1) was then transferred to a 2 l Schott flask and the pellet was removed. The supernatant (S1) was centrifuged at 15'000 x g for 30 minutes at 4°C in a 500 ml Beckman polypropylene centrifuge beaker (Beckman Avanti J-20XP; rotor JLA-10.500). The pellet (P2) was resuspended with 1:1 mannitol buffer and frozen at -80°C. The supernatant (S2) was centrifuged at 48000 x g for 50 minutes at 4°C in a 100 ml Beckman polypropylene centrifuge tube (Beckman Avanti J-20XP; rotor JA-18). The supernatant (S3) was removed and the pellet (P3) was resuspended with 1:1 mannitol buffer. P2 and P3 protein concentrations were determined using the BIORAD standard assay with bovine serum albumin as standard and measured on a NANO-Drop 1000. The membrane suspension was aliquoted (500 μl per tube) and stored at -80°C until needed.
[0152] The membrane homogenate was resuspended in binding buffer potassium phosphate 10 mM, KCl 100 mM, pH 7.4 and homogenized (Polytron PT1200E Kinematica AG) to reach the final assay concentration determined by previous experiments.
[0153] Radioligand binding assays were performed in 200 μL volumes (96-well plates) containing 100 μL of cell membranes, 1.5 nM (α5β2γ1) or 20-30 nM (α1β2γ1, α2β2γ1) of [ 3 H]RO7239181 and [0.3-10000]×10 -9The nonspecific binding of the tested compounds was 10×10 -6 (α5β2γ1) and 30×10 -6 M RO7239181 defined, and usually accounted for less than 5% (α5β2γ1) and less than 20% (α1β2γ1, α2β2γ1) of total binding. The assay was incubated at 4°C for 1 hour to reach equilibrium, and the membrane was then filtered onto a single filter (96-well white microplate bonded with GF / C filter, pre-incubated in 0.3% polyethyleneimine for 20 to 50 minutes) using a Filtermate 196 collector (Packard BioScience) and washed 4 times with cold potassium phosphate 10mM, KCl 100mM binding buffer, pH 7.4. After dehydration, the radioactivity retained by the filter was detected by liquid scintillation counting. K i Values were calculated using Excel-Fit (Microsoft) and are the average of two determinations.
[0154] The compounds of the accompanying examples were tested in the above assays and against GABA-containing A γ1 subunit receptor (e.g. α5β2γ1, α2β2γ1, α1β2γ1) replacement [ 3 H]RO7239181, it was found that the preferred compounds had a K of 100 nM or less i Most preferred are compounds with Ki (nM) < 50. Representative test results obtained by the above assays measuring binding affinity to HEK293 cells expressing human (h) receptor are shown in Table 1.
[0155] For GABA containing γ2 A Membrane preparation and binding assay of isoforms
[0156] Compounds containing GABA A The affinity of the receptor for the γ2 subunit is determined by targeting [ 3 The binding of [H]flumazenil (81.1 Ci / mmol; Roche) to HEK293F cells expressing the human (transiently transfected) receptor of the composition α1β3γ2 was measured.
[0157] Different GABA expressions A The pellets harvested from HEK293F cells expressing the γ2 receptor subtype were resuspended in mannitol buffer at pH 7.2-7.4 and used to express GABA A Cells expressing the γ1 subunit of the receptor were treated as above.
[0158] Radioligand binding assays were performed in a 200 μL volume (96-well plate) containing 100 μL of cell membranes, 1 nM concentration of [ 3 H] flumazenil and [0.1·10-3 -10]×10 -6 The nonspecific binding was 10 -5 M diazepam is defined and usually accounts for less than 5% of the total binding. The assay was incubated at 4°C for 1 h to reach equilibrium and then collected by filtration onto GF / C single filters (Packard) using a Packard harvester and washed with ice-cold wash buffer (50 mM Tris; pH 7.5). After dehydration, the radioactivity retained by the filter was detected by liquid scintillation counting. K i Values were calculated using Excel-Fit (Microsoft) and are the average of two determinations.
[0159] The compounds of the accompanying examples were tested in the above assays and against GABA from human A Receptor α1β3γ2 subunit replacement 3 H] flumazenil, and preferred compounds were found to have a K of 100 nM or higher i The most preferred value is K i Compounds with α1β3γ2 (nM)>300. In a preferred embodiment, the compounds of the present invention are A GABA receptors containing γ1 subunit A The receptor has binding selectivity. In particular, the compounds of the present invention have a "K i α1β3γ2(nM) / K i α2β2γ1(nM)” or the “Log[K i α1β3γ2(nM) / K i Representative test results obtained by the above assay for measuring binding affinity to HEK293 cells expressing the human (h) receptor are shown in Table 1 below.
[0160] Table 1
[0161]
[0162] GABA A Functional expression of receptors:
[0163] Xenopus oocyte preparation
[0164] Xenopus laevis oocytes at maturation stages V-VI were used to express GABA ACloned mRNA of receptor subunits. Oocytes prepared for RNA microinjection were purchased from Ecole, Castrop-Rauxel, Germany, and stored in modified Barth's medium (composition in mM: NaCl 88, KCl 1, NaHCO3 2.4, HEPES 10, MgSO4 0.82, CaNO3 0.33, CaCl2 0.33, pH = 7.5) at 20°C until the start of the experiment.
[0165] Xenopus oocyte microinjection
[0166] Oocytes were placed in a 96-well plate for microinjection using the Roboinject automated instrument (MultiChannel Systems, Reutlingen, Germany). Approximately 50 nL of an aqueous solution containing the desired GABA A RNA transcripts for subunits of the receptor subtype. RNA concentrations ranged from 20 to 200 pg / μL / subunit and were adjusted in pilot experiments to A Benzodiazepine receptor (BZD) binding sites were obtained with appropriate sizes for GABA response and flunitrazepam, triazolam and midazolam, reference benzodiazepines Maximal effect of positive allosteric modulators (PAMs) Oocytes were kept in modified Barth's medium (composition in mM: NaCl 88, KCl 1, NaHCO3 4, HEPES 10, MgSO4 0.82, CaNO3 0.33, CaCl2 0.33, pH = 7.5) at 20°C until the start of the experiment.
[0167] Electrophysiology
[0168] Electrophysiological experiments were performed using a Roboocyte instrument (MultiChannel Systems, Reutlingen, Germany) on days 3 to 5 after microinjection of mRNA. During the experiment, oocytes were continuously perfused with a solution containing (in mM) NaCl 90, KCl1, HEPES 5, MgCl2 1, CaCl21 (pH 7.4). The oocytes were pierced with two glass microelectrodes (resistance: 0.5 to 0.8 MΩ), which were filled with a solution containing KCl 1M + potassium acetate 1.5M and voltage clamped to -80 mV. Recordings were performed at room temperature using a Roboocyte two-electrode voltage clamp system (Multichannel system). After an initial equilibration period of 1.5 min, a concentration of GABA was added for 1.5 min, which triggered a maximum current response of approximately 20% (EC 20 ). After another 2.5-min rest period, GABA was added again, eliciting a response of similar amplitude and shape. 0.5 min after the second GABA application, when GABA was still present, the response was induced at a rate equivalent to its K i Test compounds were added at a concentration approximately 30 times that of α2β2γ1. Current traces were recorded at a digitization rate of 10 Hz during and before and after GABA application.
[0169] Test each compound and concentration on at least 3 oocytes. Different oocytes were used for different compound concentrations. Reference PAM, flunitrazepam, triazolam, and midazolam in α2β2γ1GABA expressing oocytes A The receptor subtype potentiated GABA-induced currents by approximately 60%.
[0170] Data analysis
[0171] During analysis, the digitized current traces of the first GABA response and the second GABA response were superimposed and, if necessary, rescaled to equal maximum amplitudes. The ratio between the two responses within the time interval of test compound application was calculated point by point. The extreme value of the resulting "ratio trace" was taken as the efficacy ("fold increase") of the compound, expressed as "GABA EC 20 Regulation rate %” (100*(fold increase - 1)).
[0172] The results are shown in Table 2.
[0173] Table 2
[0174]
[0175] Example 4 - Reference Compounds
[0176] The following benzodiazepines were tested Reference compounds (classic commercially available benzodiazepines Drugs) and their structural analogs on GABA A Receptor α1β2γ1 and α2β2γ1 subtypes and GABA A The results are shown in Table 3.
[0177]
[0178] Table 3
[0179]
[0180] Example 5 - In vitro autoradiography
[0181] Coronal brain sections from GABAAγ1 receptor knockout mice (C57BL / 6NTac-Gabrg1) and wild-type controls were used for [ 3 H]-(I) and [ 3 H]-(II) autoradiographic analysis. Tissue sections (10 μm) were cut in a cryostat, mounted on microscope slides after thawing, and analyzed at room temperature in the presence of 0.3 nM radioligand (specific for [ 3 H]-(II) and [ 3 H]-(I) molar activity of 83Ci / mmol and 81Ci / mmol respectively) incubation buffer (50mM Tris-HCl, pH7.4) for 30 minutes. After incubation, all slices were rinsed three times in ice-cold washing buffer (50mM Tris-HCl, pH7.4) for 10 minutes and soaked three times in 4°C distilled water. The slide-mounted brain slices were dried in a ventilated refrigerator for at least 2 hours and exposed to Fuji imaging plates for 5 days. The imaging plates were scanned at a resolution of 25μm in a Fujifilm high-resolution plate scanner. Visualization and quantification of autoradiography were performed by MCIDTM image analysis program.
[0182] result
[0183] The autoradiograms showed a distributed binding pattern consistent with the expected enriched expression of the GABAAγ1 receptor subtype in limbic brain regions such as the amygdala ( Figure 1 ). Radioligand binding was significantly reduced in brain sections from GABAAγ1 receptor knockout mice. [ 3 H]-(II) showed 97% specific binding in the amygdala, while [ 3H]-(I) showed 65% specific binding.
[0184] Example 6 - In vivo PET scan
[0185] PET imaging experiments were performed on male East African baboons, Papio papio, to examine in vivo [ 11 C]-(I) and [ 11 C]-(II) characteristics. The final radiotracer product was radiochemically pure (>95%) 40 min after the end of synthesis, with an average final calculated specific activity of >555 GBq / μmol. The PET camera used was a Siemens HRRT with an in-plane field of view (FOV) of 30 cm and an axial FOV of 24 cm. Each dynamic PET scan began with an intravenous bolus of radiotracer (approximately 700 MBq) and lasted for 90 min in 3D list mode. A set of volumes of interest (VOIs) for 16 brain regions were defined on the MRI of individual animals with reference to a standard VOI template. The VOIs were transferred to PET space using registration parameters to generate time-activity curves (TACs) of brain regions.
[0186] result
[0187] Following intravenous injection in baboons, both PET tracers showed rapid initial brain uptake (peaking before or around 10 min in most regions but slower peaking in lower peak regions) and gradual clearance, as shown in Figure 2. Figure 2 As shown. 11 C]-(II) peaks are usually larger than [ 11 C]-(I) is earlier, indicating that it enters the brain faster. 11 The slower clearance of [C]-(I) suggests slower dissociation of this tracer or more likely higher nonspecific binding. In summary, both tracer candidates exhibited good transport across the blood-brain barrier, low nonspecific retention, and appropriate clearance kinetics. Overall, these properties make both radiotracers promising PET imaging agents for visualization of GABAAγ1 receptor subtypes.
Claims
1. A compound of formula (I) or formula (II) or a pharmaceutically acceptable salt thereof, wherein the compound comprises a radioactive label.
2. The compound of formula (I) or formula (II) according to claim 1, wherein the radioactive label is selected from 11 C and 3 H.
3. A compound of formula (I) or formula (II) according to claim 2, which is selected from the group consisting of as well as or a pharmaceutically acceptable salt thereof.
4. The compound of formula (I) or formula (II) according to claim 3, which is or a pharmaceutically acceptable salt thereof.
5. The compound of formula (I) or formula (II) according to claim 3, which is or a pharmaceutically acceptable salt thereof.
6. The compound of formula (I) or formula (II) according to claim 3, which is or a pharmaceutically acceptable salt thereof.
7. The compound of formula (I) or formula (II) according to claim 3, which is or a pharmaceutically acceptable salt thereof.
8. A study on GABA in mammals A γ1 A method of performing diagnostic imaging, the method comprising: (a) administering to the mammal a detectable amount of a radiolabeled compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof; as well as (b) Detection and GABA A The radiolabeled compound when γ1 associated.
9. The method of claim 8, wherein the detecting is accomplished via autoradiography and / or positron emission tomography (PET).
10. A radiolabeled compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof for use in GABA A Used in γ1 occupancy studies.
11. A radiolabeled compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof for use in a method according to claim 8 or 9.
12. Use of a radiolabeled compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof in a method according to claim 8 or 9.
13. Use of a radiolabeled compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof for preparing a medicament for the regulation of GABA in the brain of a mammal A γ1 Perform diagnostic imaging.
14. The invention as hereinbefore described.
